Phase 2 N=12 GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
Obesity, Morbid
Primary: Change in Body Mass Index (BMI) — -0.9; 0.84 change in kg/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=98 Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
Cervical Cancer · Cervical Intraepithelial Neoplasia Grade 1 · Human Papilloma Virus Infection
Primary: Complete Response - Clearance of Oncogenic Human Papillomavirus (HPV) and Complete Colposcopic, Histologic and Cytologic Clearance of Disease — 7; 6 participants
Phase 2 N=9 Imatinib in Systemic Sclerosis
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Phase 2 N=60 A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
Japanese Encephalitis
Primary: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain Up to 28 Days After the First Active Vaccination With Either ChimeriVax™-JE or…
Phase 2 N=103 Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
Breast Cancer
Primary: Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as…
Phase 2 N=50 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
Colorectal Adenocarcinoma
Primary: Overall Response — 0 percentage of participants
Phase 2 N=107 Interactive Motivational Media for Perinatal Drug Abuse - 3
Substance-Related Disorders
Primary: Number of Participants With Drug Use at 3 Months — 49; 48 participants
Phase 2 N=6 Rapid Antidepressant Effects of Yohimbine in Major Depression
Depression, Involutional · Major Depresssion
Primary: Hamilton Depression Rating Scale (6 Items) — 8.776; 9.780 Units on a scale — p=.527
Phase 2 N=59 Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.
Anemia
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.22; 11.33; 0.10 g/dL
Phase 2 N=249 Study Evaluating Pneumococcal Vaccine in Healthy Infants
Healthy Subjects · Pneumococcal Infections
Primary: Percentage of Participants Reporting Pre-Specified Local Reactions — 34.5; 43.5; 28.2; 36.4 percentage of participants
Phase 2 N=58 Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: UPDRS Part III OFF — -7.21; -6.91 units on a scale
Phase 2 N=104 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
Phase 2 N=66 Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Exercise Induced Asthma
Primary: Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks — -5.85; 0.61; -5.24 Percent change
Phase 2 N=12 Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
HIV Infections · HSV-2 Genital Herpes
Primary: HIV Antiviral Activity of Each of the Cervico-vaginal Samples (Samples Taken From the Vagina Using the Softcup) — 96 percent anti-viral activity
Phase 2 N=138 Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants